Therapeutic efficacy and safety of Botulinum Toxin A Therapy in Trigeminal Neuralgia: a systematic review and meta-analysis of randomized controlled trials

Journal of Headache and Pain

Volumn 17, Issue 1, 2016, Pages

  Morra, Mostafa Ebraheem ^a   Elgebaly, Ahmed ^a   Elmaraezy, Ahmed ^a   Khalil, Adham M ^b   Altibi, Ahmed M A ^c   Vu, Tran Le Huy ^d   Mostafa, Mostafa Reda ^e   Huy, Nguyen Tien ^f,g   Hirayama, Kenji ^f  

^a AL AZHAR UNIVERSITY   (Egypt)

^b ZAGAZIG UNIVERSITY   (Egypt)

^c UNIVERSITY OF JORDAN   (Jordan)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e TANTA UNIVERSITY   (Egypt)

^f NAGASAKI UNIVERSITY   (Japan)

^g UNIVERSITY OF MEDICINE AND PHARMACY AT HO CHI MINH CITY   (Viet Nam)

Author keywords

Botulinum; BTX A; Clinical trials; Meta analysis; Systematic review; Trigeminal neuralgia

Indexed keywords

BOTULINUM TOXIN A; PLACEBO;

ADVERSE OUTCOME; DRUG EFFICACY; DRUG SAFETY; EDEMA; FACE ASYMMETRY; FOLLOW UP; HEMATOMA; HUMAN; META ANALYSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT OUTCOME; TRIGEMINUS NEURALGIA; CHEMICALLY INDUCED; DRUG EFFECTS; FACTUAL DATABASE; PAIN MEASUREMENT; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRIGEMINAL NEURALGIA;

BOTULINUM TOXINS, TYPE A; DATABASES, FACTUAL; EDEMA; HEMATOMA; HUMANS; PAIN MEASUREMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TRIGEMINAL NEURALGIA;

EID: 84980484371     PISSN: 11292369     EISSN: 11292377     Source Type: Journal    
DOI: 10.1186/s10194-016-0651-8     Document Type: Review

References (35)

1. Devor M, Wood I, Sharav Y, Zakrzewska JM (2008) Trigeminal neuralgia during sleep. Pain Pract 8(4):263–8. http://onlinelibrary.wiley.com/doi/10.1111/j.1533-2500.2008.00214.x/full
2. Hals EKB, Stubhaug A (2011) Mental and somatic co-morbidities in chronic orofacial pain conditions: Pain patients in need of multiprofessional team approach. Scand J Pain 2(4):153–154
3. Zakrzewska JM (2013) Multi-dimensionality of chronic pain of the oral cavity and face. J Headache Pain 14:37
4. Campos WK, Linhares MN (2011) A prospective study of 39 patients with trigeminal neuralgia treated with percutaneous balloon compression. Arq Neuropsiquiatr 69(2A):221–6
5. Zakrzewska JM, McMillan R (2011) Trigeminal neuralgia: the diagnosis and management of this excruciating and poorly understood facial pain. Postgrad Med J 87(1028):410–6
6. Wu T-H, Hu L-Y, Lu T, Chen P-M, Chen H-J, Shen C-C, Wen C-H (2015) Risk of psychiatric disorders following trigeminal neuralgia: a nationwide population-based retrospective cohort study. J Headache Pain 16:64
7. Jia D, Li G (2010) Bioresonance hypothesis: a new mechanism on the pathogenesis of trigeminal neuralgia. Med Hypotheses 74(3):505–7
8. Obermann M, Holle D, Katsarava Z (2011) Trigeminal neuralgia and persistent idiopathic facial pain. Expert Rev Neurother 11(11):1619–29
9. Cruccu G, Gronseth G, Alksne J, Argoff C, Brainin M, Burchiel K, Nurmikko T, Zakrzewska JM (2008) AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol 15(10):1013–28
10. Cruccu G, Truini A (2013) Refractory trigeminal neuralgia. Non-surgical treatment options. CNS Drugs 27(2):91–6
11. Chakravarthi PS, Ghanta R, Kattimani V (2011) Microvascular decompression treatment for trigeminal neuralgia. J Craniofac Surg 22(3):894–898
12. Park K-J, Kano H, Berkowitz O, Awan NR, Flickinger JC, Lunsford LD, Kondziolka D (2011) Computed tomography-guided γ knife stereotactic radiosurgery for trigeminal neuralgia. Acta Neurochir (Wien) 153(8):1601–1609
13. Koopman JSHA, De Vries LM, Dieleman JP, Huygen FJ, Stricker BHC, Sturkenboom MCJM (2011) A nationwide study of three invasive treatments for trigeminal neuralgia. Pain 152(3):507–513
14. Taylor JC, Brauer S, Espir ML (1981) Long-term treatment of trigeminal neuralgia with carbamazepine. Postgrad Med J 57(663):16–8
15. Taha JM, Tew JM (1997) Treatment of trigeminal neuralgia by percutaneous radiofrequency rhizotomy. Neurosurg Clin N Am 8(1):31–9
16. Heinskou T, Maarbjerg S, Rochat P, Wolfram F, Jensen RH, Bendtsen L (2015) Trigeminal neuralgia--a coherent cross-specialty management program. J Headache Pain 16:66
17. Oguma K, Fujinaga Y, Inoue K (1997) Clostridium Botulinum Toxin. Toxin Rev 16(4):253–266
18. Humeau Y, Doussau F, Grant NJ, Poulain B (2000) How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie 82(5):427–446
19. Pearce LB, First ER, Maccallum RD, Gupta A (1997) Pharmacologic characterization of Botulinum toxin for basic science and medicine. Toxicon 35(9):1373–1412
20. Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30(7):793–803
21. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30(7):804–14
22. Micheli F, Scorticati MC, Raina G (2002) Beneficial effects of botulinum toxin type a for patients with painful tic convulsif. Clin Neuropharmacol 25(5):260–2. http://journals.lww.com/clinicalneuropharm/Abstract/2002/09000/Beneficial_Effects_of_Botulinum_Toxin_Type_A_for.6.asp
23. Wu C-J, Lian Y-J, Zheng Y-K, Zhang H-F, Chen Y, Xie N-C, Wang L-J (2012) Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial. Cephalalgia 32(6):443–50
24. Zhang H, Lian Y, Ma Y, Chen Y, He C, Xie N, Wu C (2014) Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial. J Headache Pain 15:65
25. Zúñiga C, Piedimonte F, Díaz S, Micheli F (2013) Acute Treatment of Trigeminal Neuralgia With Onabotulinum Toxin A. Clin Neuropharmacol 36(5):146–150
26. Shehata HS, El-Tamawy MS, Shalaby NM, Ramzy G (2013) Botulinum toxin-type A: could it be an effective treatment option in intractable trigeminal neuralgia? J Headache Pain 14:92
27. Zakrzewska JM (2010) Medical management of trigeminal neuropathic pains. Expert Opin Pharmacother 11(8):1239–54
28. Bond AE, Zada G, Gonzalez AA, Hansen C, Giannotta SL (2010) Operative strategies for minimizing hearing loss and other major complications associated with microvascular decompression for trigeminal neuralgia. World Neurosurg 74(1):172–7
29. Piovesan EJ, Teive HG, Kowacs PA, Della Coletta MV, Werneck LC, Silberstein SD (2005) An open study of botulinum-A toxin treatment of trigeminal neuralgia. Neurology 65(8):1306–1308
30. Cui M, Khanijou S, Rubino J, Aoki KR (2004) Subcutaneous administration of botulinum toxin a reduces formalin-induced pain. Pain 107(1–2):125–133
31. Xiao L, Cheng J, Zhuang Y, Qu W, Muir J, Liang H, Zhang D (2013) Botulinum toxin type A reduces hyperalgesia and TRPV1 expression in rats with neuropathic pain. Pain Med 14(2):276–86
32. Matak I, Bach-Rojecky L, Filipović B, Lacković Z (2011) Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience 186:201–7
33. Matak I, Riederer P, Lacković Z (2012) Botulinum toxin’s axonal transport from periphery to the spinal cord. Neurochem Int 61(2):236–9
34. Wu C, Xie N, Lian Y, Xu H, Chen C, Zheng Y, Chen Y, Zhang H (2016) Central antinociceptive activity of peripherally applied botulinum toxin type A in lab rat model of trigeminal neuralgia. Springerplus 5:431
35. Hu Y, Guan X, Fan L, Li M, Liao Y, Nie Z, Jin L (2013) Therapeutic efficacy and safety of botulinum toxin type A in trigeminal neuralgia: a systematic review. J Headache Pain 14(1):72